ERBB2 and breast carcinoma: Thus, bispecific antibodies targeting two HER2 epitopes in HER2-positive breast cancer can enhance HER2 clustering by facilitating the internalization of endosomes, coupled with inhibition of HER2 recycling back to the cell surface [67].